Objective: The purpose of this study was to evaluate the effect of maternal nifedipine on fetal survival when started 24-48 hours before selective fetoscopic laser photocoagulation (SFLP).
Study Design: We conducted a case control study of consecutive cases of twin-twin transfusion syndrome (TTTS) in which TTTS cardiomyopathy was treated with maternal nifedipine 24-48 hours before SFLP, compared with gestational age and stage-matched control cases. The primary outcome was recipient and donor survival.
Results: One hundred forty-one cases of TTTS were treated with nifedipine, and 152 gestational age- and stage-matched control cases were analyzed. There was a significant increase in overall fetal survival in nifedipine-treated cases compared with control cases (237/284 [83%] vs 232/308 [75%]; P = .015). There is an increase in survival of recipients who were treated with nifedipine in stage IIIA (100% vs 81%; P = .021) and IIIB (93% vs 71%; P = .014); however, there was no difference in donor survival.
Conclusion: Maternal nifedipine is associated with improved recipient survival in TTTS that undergoes SFLP. This is the first study to suggest a benefit of adjunctive maternal medical therapy in patients with TTTS who undergo SFLP.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ajog.2010.06.032 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Exploring Pharmacological and Non-Pharmacological Approaches to Managing Hypertension During Pregnancy: A Systematic Review.
Cureus
December 2024
Internal Medicine, Omdurman Islamic University, Khartoum, SDN.
This systematic review aimed to explore the efficacy of both pharmacological and non-pharmacological interventions in managing hypertension during pregnancy. It analyzed high-quality randomized controlled trials (RCTs), focusing on outcomes related to maternal and fetal health. The findings demonstrated that antihypertensive medications, particularly labetalol and nifedipine, effectively reduced the risks of severe preeclampsia (PE), preterm birth, and other complications.
View Article and Find Full Text PDFAmlodipine versus nifedipine ER for the management of postpartum hypertension: a noninferiority randomized controlled trial.
Am J Obstet Gynecol MFM
December 2024
Prisma Health Upstate/University of South Carolina School of Medicine Greenville, Greenville, SC (Pratt and Carlson).
Background: Postpartum hypertension is an increasingly prevalent problem and optimizing its treatment is imperative in reducing maternal morbidity and improving long-term health outcomes. Despite this, data on treatment of postpartum hypertension is limited. While most available studies focus on labetalol and nifedipine ER, these medications are not frequently used for hypertension treatment in the non-obstetric setting.
View Article and Find Full Text PDFMagnesium sulfate versus nifedipine for tocolysis: meta-analysis of randomized controlled trials.
Women Health
January 2025
Postgraduate Program in Pharmaceutical Sciences, Health Science Center, Federal University of Rio Grande do Norte, Natal, Brazil.
Article Synopsis
- * The analysis included 15 randomized clinical trials involving 2,186 pregnant women and found that nifedipine was generally more effective than magnesium sulfate, although both drugs similarly prolonged pregnancy by 48 hours in some cases.
- * Magnesium sulfate had more side effects than nifedipine, and further research is needed to confirm these findings through large-scale studies.
Daily versus Twice Daily Nifedipine for Blood Pressure Control in Pregnancy and Postpartum.
Am J Perinatol
December 2024
Division of Maternal-Fetal Medicine, Department of Obstetrics, Gynecology, and Reproductive Science, Icahn School of Medicine at Mount Sinai, New York, New York.
Article Synopsis
- The study aimed to compare the effectiveness of 60mg daily (QD) extended-release nifedipine versus 30mg twice daily (BID) for controlling blood pressure in pregnant patients before and after delivery.
- Conducted as a retrospective review at Mount Sinai Health System, the research included 237 patients with hypertensive disorders of pregnancy and evaluated the need for adjusting medication dosages.
- Results showed no significant differences in blood pressure management or emergency treatment needs between the two dosing regimens, suggesting that once-daily dosing may be more convenient for patients without compromising effectiveness.
Short-Acting Oral Nifedipine versus Intravenous Labetalol for the Control of Severe Hypertension in the Postpartum Period: A Retrospective Cohort Study.
Am J Perinatol
October 2024
Department of Cardiology, Smidt Heart Institute, Cedars Sinai Medical Center, Los Angeles, California.
Objective: This study aimed to compare the effectiveness of oral short-acting (SA) nifedipine with intravenous (IV) labetalol for the treatment of postpartum (PP) severe hypertension.
Study Design: We conducted a retrospective cohort study of women who delivered at a tertiary care facility between January and December 2018, had not previously received antihypertensive medication, and required treatment for PP severe hypertension defined as systolic blood pressure (SBP) ≥ 160 mm Hg and/or diastolic blood pressure (DBP) ≥110 mm Hg. Exposure groups were defined by the receipt of either oral SA nifedipine or IV labetalol.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!